Genomic Health Says International Markets, New Oncotype Indications are Key to Future Growth

While Genomic Health projects "more modest" growth for its legacy node-negative breast cancer business over the next year, newer markets in which the company is still working to secure reimbursement still represent a significant opportunity for expansion in the years ahead.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.